|
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company operates in three business segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. In July 2009, Johnson & Johnson completed the acquisition of Cougar Biotechnology, Inc. with approximately 95.9% interest in Cougar Biotechnology's outstanding common stock. In September 2009, Elan Corporation, plc and Johnson & Johnson announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer`s Immunotherapy Program (AIP). In March 2010, Hypermarcas SA acquired 99.99% of Versoix Participacoes Ltda from the Company.
|
|
Around The Net
You are reading news provided by a variety of web sources.
Drug Pipeline
| Drug Name | Type Of Drug | FDA Status | Drug Phase |
| Nucynta |
Pain Management
| Pending Decision | Phase 3 |
Events
FDA Decision:
FDA decision
(relates to the drug Nucynta)
Add New Event
In order to write a comment you must first login.
Login or Register (for free!)
Add Event
Important Links
No links found.
Add New Link
In order to write a comment you must first login.
Login or Register (for free!)
Add Link
|
JNJ
$58.93
9/3/2010 4:00:00 PM
Sponsors
|